



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

7 Jun 2021 (#16)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

**Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)**

## Important Notices

**[NOT-OD-21-128](#) Updated Process for Submission of Federal Financial Reports for Closed Payment Management System Subaccounts.** The purpose of this Notice is to provide instructions to NIH recipients who need to submit an SF-425 Federal Financial Report (FFR) for a closed subaccount (e.g. "C" status) in the HHS Payment Management System (PMS).

**[NOT-OD-21-138](#) NIH Final Federal Financial Reports (FFRs) will be converted to Interim Annual Reports in the Payment Management System.** The purpose of this Notice is to provide an update to NIH recipients who need to submit an SF-425 Federal Financial Report (FFR).

**[NOT-HD-21-039](#) Notice of Intent to Publish a Funding Opportunity Announcement for Innovative Therapies and Tools for Screenable Disorders in Newborns.** The purpose of this Notice is to inform the scientific community that the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) plans to reissue three Funding Opportunity Announcements (FOAs), [PAR-18-689](#), [PAR-18-690](#), and [PAR-18-691](#), "Innovative Therapies and Tools for Screenable Disorders in Newborns. When reissued, these FOAs will continue to use the R01, R03, and R21 activity codes, respectively, and will continue to be clinical trial optional. The Specific Areas of Research Interest in these FOAs will be updated to include new and revised research priorities. This Notice informs potential applicants of the future availability of continued opportunities to submit applications beyond the 8 May 2021 expiration of the FOAs. Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Funding Opportunity Announcements (FOA)

### 1. Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Research Project (U01 Clinical Trial optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AA-21-010](#)

**Type:** U01

**Application Due Date:** 16 August 2021. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** The National Institute on Alcohol Abuse and Alcoholism ([NIAAA](#)) seeks applications to continue the previously funded “Collaborative Initiative on Fetal Alcohol Spectrum Disorders” (CIFASD). Responsive applications are expected to address urgent and important unmet needs in the fetal alcohol spectrum disorders (FASD) field through an integrated and multidisciplinary research approach. These unmet needs include identifying FASD cases early and accurately, improving interventions to mitigate FASD outcomes; expanding basic and mechanistic understanding of alcohol teratogenesis aimed at accelerated translation, and reducing prenatal alcohol exposure and the incidence of FASD. Cooperative Agreement (U01) applications in response to this FOA should propose individual clinical or basic research projects.

**Budget:** NIAAA intends to commit a combined \$4.6 million in total costs in FY2022 to fund this FOA and its companion FOAs. Up to eight U01 applications are expected to be funded from this FOA. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 2. Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Developmental Project (UH2 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AA-21-014](#)

**Type:** UH2

**Application Due Date:** 16 August 2021. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** National Institute on Alcohol Abuse and Alcoholism ([NIAAA](#)) seeks applications to continue the previously funded “Collaborative Initiative on Fetal Alcohol Spectrum Disorders” (CIFASD). Responsive applications are expected to address urgent and important unmet needs in the fetal alcohol spectrum disorders (FASD) field through an integrated and multidisciplinary research approach. These unmet needs include identifying FASD cases early and accurately, improving interventions to mitigate FASD outcomes; expanding basic and mechanistic understanding of alcohol teratogenesis aimed at accelerated translation, and reducing prenatal alcohol exposure and the incidence of FASD. Cooperative Agreement (UH2) applications in response to this FOA should propose exploratory/developmental projects of the CIFASD consortium.

**Budget:** NIAAA intends to commit a combined \$4.6 million in total costs in FY2022 to fund this FOA and its companion FOAs ([RFA-AA-21-010](#), [RFA-AA-21-011](#), [RFA-AA-21-012](#), [RFA-AA-21-013](#)). Up to three UH2 applications are expected to be funded from this FOA. The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

### 3. Exploratory Studies to Investigate the Mechanisms of Interrelationship Between Sleep and Substance Use Disorders (R61/R33 Clinical Trials Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-DA-22-016](#)

**Type:** R61/R33

**Application Due Date:** 14 October 2021. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** The purpose of this FOA is to support research project applications that are developmental and exploratory in nature to expand our knowledge on the basic neurobiology of the interrelationship between sleep and substance use disorders (SUDs). These mechanistic studies will not only offer an insight into the fundamental processes that link substance use disorders to disorders of sleep regulation and vice-versa but may also have implications for managing the risk for the development of SUDs and identifying new targets for prevention and therapeutics.

**Budget:** National Institute on Drug Abuse ([NIDA](#)) intends to commit \$ 3.5M in FY 2022 to fund 2-5 awards across this and the companion FOAs. Application direct costs are limited to \$250,000 during each year of the R61 phase and \$500,000 during each year of the R33 phase. The maximum period of the combined R61 and R33 phases is 5 years, with up to 2 years for the R61 phase and up to 3 years for the R33 phase. The scope of the proposed project should determine the requested project period.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105